Pfizer stops clinical trial as Paxlovid fails to prove efficacy in patients with low risk of severe disease. Pfizer’s COVID-19 vaccine,...

The American giant gains access to Biohaven’s late-stage migraine nasal spray through multi-billion transaction. A few days ago, the...

The perception that the Omicron variant is not severe has hampered demand. The demand for Pfizer’s antiviral treatment Paxlovid has...

Paxlovid has shown to reduce the risk of death and hospitalisations by 90%. Britain has added Pfizer’s antiviral COVID-19 treatment,...

Scientists will look into whether Paxlovid reduces the risk of death among patients admitted to hospitals. In a major British trial,...